舒格利单抗单药治疗复发或难治性结外自然杀伤/T细胞淋巴瘤(GEMSTONE-201):单臂、多中心、II期研究结果
GEMSTONE-201是一项单臂多中心II期研究,评估舒格利单抗(抗PD-L1单抗)治疗复发或难治性结外自然杀伤/T细胞淋巴瘤的疗效与安全性。截至2022年2月23日,80例患者入组,中位随访18.7个月;独立影像评审委员会评估的客观缓解率为44.9%(95%CI 33.6至56.6),完全缓解率35.9%,12个月缓解持续时间率82.5%(95%CI 62.0至92.6)。
要点
- 舒格利单抗1,200 mg静脉给药每3周一次,最长24个月,用于复发或难治性结外自然杀伤/T细胞淋巴瘤。
- 独立影像评审委员会评估客观缓解率44.9%(95%CI 33.6至56.6),完全缓解率35.9%,部分缓解率9.0%。
- ≥3级治疗中出现的不良事件发生于32例(40.0%)患者,多数不良事件为1-2级。
核心结论
- 舒格利单抗在复发或难治性结外自然杀伤/T细胞淋巴瘤中显示出稳健且持久的抗肿瘤活性,耐受性良好,安全性特征与该类药物预期相符。
研究设计与样本
- 单臂、多中心、II期研究,评估舒格利单抗治疗复发或难治性结外自然杀伤/T细胞淋巴瘤的疗效与安全性。
- eligible患者接受舒格利单抗1,200 mg静脉给药,每3周一次,最长24个月或直至疾病进展、死亡或退出研究。
- 主要终点为独立影像评审委员会评估的客观缓解率;关键次要终点包括研究者评估的客观缓解率、完全缓解率、缓解持续时间和安全性。
- 截至数据截止日2022年2月23日,共入组80例患者,中位随访18.7个月。
- 基线时54例(67.5%)为IV期疾病,39例(48.8%)既往接受过≥2线系统性治疗。
主要发现
- 独立影像评审委员会评估的客观缓解率为44.9%(95%CI 33.6至56.6);28例(35.9%)达到完全缓解,7例(9.0%)达到部分缓解。
- 12个月缓解持续时间率为82.5%(95%CI 62.0至92.6)。
- 研究者评估的客观缓解率为45.6%(95%CI 34.3至57.2),24例(30.4%)达到完全缓解。
- 大多数治疗中出现的不良事件为1-2级;≥3级事件发生于32例(40.0%)患者。
关键数值与推荐
- 舒格利单抗给药方案:1,200 mg静脉给药,每3周一次,最长24个月或直至疾病进展、死亡或退出研究。
- 主要终点独立影像评审委员会评估的客观缓解率44.9%(95%CI 33.6至56.6)。
- 完全缓解率35.9%(独立影像评审委员会评估),部分缓解率9.0%。
- 12个月缓解持续时间率82.5%(95%CI 62.0至92.6)。
- 研究者评估的客观缓解率45.6%(95%CI 34.3至57.2),完全缓解率30.4%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) is a rare and aggressive type of non-Hodgkin lymphoma with limited treatment options. This phase II study evaluated the efficacy and safety of sugemalimab, an anti-PD-L1 monoclonal antibody, in R/R ENKTL. METHODS: Eligible patients received sugemalimab 1,200 mg intravenously once every 3 weeks for up to 24 months or until progression, death, or study withdrawal. The primary end point was objective response rate (ORR) assessed by an independent radiologic review committee. Key secondary end points included ORR assessed by the investigators, complete response rate, duration of response, and safety. RESULTS: At the data cutoff (February 23, 2022), 80 patients were enrolled and followed for a median of 18.7 months. At baseline, 54 (67.5%) had stage IV disease and 39 (48.8%) had received ≥2 lines of prior systemic therapy. Independent radiologic review committee-assessed ORR was 44.9% (95% CI, 33.6 to 56.6); 28 (35.9%) patients achieved a complete response and seven (9.0%) achieved a partial response, with a 12-month duration of response rate of 82.5% (95% CI, 62.0 to 92.6). Investigator-assessed ORR was 45.6% (95% CI, 34.3 to 57.2), and 24 (30.4%) patients achieved a complete response. Most treatment-emergent adverse events were grade 1-2 in severity, and grade ≥ 3 events were reported in 32 (40.0%) patients. CONCLUSION: Sugemalimab showed robust and durable antitumor activity in R/R ENKTL. Treatment was well tolerated with expected safety profile for this drug class.
引用
- Huang H, Tao R, Hao S, et al. Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study. J Clin Oncol. 2023. PMID: 36996373. doi:10.1200/JCO.22.02367
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。